## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### TECHNOLOGY APPRAISAL PROGRAMME

#### Equality impact assessment – Scoping

# STA Abatacept for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs

# Batch 51

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No issues raised.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

N/A

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Technology Appraisals: Scoping

Equality impact assessment for the single technology appraisal for abatacept for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs

N/A

## Approved by Associate Director (name): Helen Knight

Date: 22/09/2017

Technology Appraisals: Scoping Equality impact assessment for the single technology appraisal for abatacept for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs